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Angiotensin-converting enzyme (ACE) I/D genotype and re- diabetic nephropathy in insulin-dependent diabetes mel-
nal ACE gene expression. litus [4] and non–insulin-dependent diabetes mellitus
Background. The angiotensin-converting enzyme (ACE) I/D [5, 6] and the progression of diabetic nephropathy ingenotype affects serum ACE levels and the onset and progres-
non–insulin-dependent diabetes mellitus [7] has been re-sion of renal disease, but little is known about the mechanism.
ported. However, many conflicting reports also existWe investigated a possible association between the ACE I/D
genotype and renal ACE mRNA levels in healthy subjects. [8–10]. To resolve this confusion, not only statistical stud-
Methods. Renal biopsy samples were obtained from 50 healthy ies but also more fundamental studies to determine the
kidney donors. The ACE I/D genotype was determined by
mechanism of the association of ACE gene I/D genotype,polymerase chain reaction (PCR). Renal ACE mRNA quanti-
renal ACE mRNA, and renal ACE levels are necessary.fication was performed by competitive RNA-PCR. In situ hy-
bridization (ISH) for ACE mRNA on renal biopsy specimens The lack of detailed studies on ACE I/D genotype and
was also performed. kidney ACE mRNA expression may be attributed to
Results. The number of ACE transcripts in 100 ng of total the fact that measurements of human kidney samplesRNA was significantly (P  0.01) lower in subjects with II ge-
are possible in only restricted situations. In the presentnotype (5.6  5.3  105, N  20) compared with those with
study, we investigated a possible association betweenthe ID (17.9 13.6 105, N 23) or the DD genotype (36.9
14.6  105, N  7) in healthy donors. The ISH studies showed renal ACE mRNA levels and the ACE I/D genotype in
that both tubular and glomerular ACE mRNA expressions healthy subjects.
were weak in subjects with the II genotype, intermediate in
subjects with ID genotype, and strong in subjects with DD
genotype. METHODSConclusions. It is suggested that renal ACE gene expression
is associated with the ACE I/D genotype in healthy Japanese Subjects
subjects. Inclusion criteria were healthy Japanese with normal
blood pressure (systolic blood pressure140 mm Hg and
diastolic blood pressure 90 mm Hg) seen as kidney
The angiotensin-converting enzyme (ACE) gene I/D donors at Toho University Hospital from 1995 to 1999.
genotype is associated with plasma, cellular, and tissue Exclusion criteria were presence of acute and chronic
ACE levels. Plasma ACE levels are the highest in sub- disease, body mass index 28 kg/m2, antihypertensive
jects with the DD genotype, intermediate in subjects with drug intake. Blood pressure, serum creatinine, and serum
the ID genotype, and the lowest in subjects with the II ACE levels were measured one day before the kidney
genotype [1]. T lymphocytes [2] and cardiac ACE [3] are donation. Blood pressure was measured in the sitting
increased in subjects with the DD genotype. An associa-
position with mercury sphygmomanometer. Three mea-
tion between ACE gene I/D genotype and the onset of
surements were taken at five-minute intervals. Analysis
was performed on the mean of all three measurements.
Fifty kidney donors were consecutively included for thisKey words: kidney, ACE genotypes, progressive renal disease, diabetic
nephropathy, ethnic genotype, chronic renal disease. study, and informed consent as stipulated by the Human
Subjects Committee of Toho University was obtained
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including acute tubular necrosis (ATN) and transmitted scribed in the same tube and coamplified by the same
primer. Sense and antisense primer were selected fromnephropathy.
the human cDNA sequences of ACE (sense primer, 1656-
Determination of ACE I/D genotype 1675 5-GCAAGGAGGCAGGCTATGAG-3; antisense
primer, 2412-2431 5-CGGGTAAAACTGGAGGATGGenomic DNA extracted from peripheral white blood
cells was used as the template for polymerase chain reac- G-3). Conditions for reverse transcription and PCR
were from the protocol of Studer et al [13]. The PCRtion (PCR) of intron 16 of the ACE gene, which contains
polymorphic markers. The primers and PCR condition products indicated as the ACE target (776 bp) and com-
petitor (307 bp) were separated by electrophoresis onwere from the protocol of Rigat et al [11]. To increase
the specificity of DD genotyping, we performed the sec- 5% polyacrylamide gel. In hot PCR, the gel was dried,
and the radioactivity was evaluated with an Instant Im-ond PCR according to the report by Yoshida et al [12],
using the insertion-specific primer pair. ager (Packard, Tokyo, Japan). To correct for differences
in the count of C, which was 87 in the ACE competitor
Angiotensin-converting enzyme mRNA quantification and 216 in the ACE target PCR product, the radioactivi-
by competitive RNA-PCR ties of the band of the ACE target were divided by 2.483
(216/87). The values of the samples from hot PCR wereA portion of each renal biopsy samples was immediately
frozen in liquid nitrogen and stored at 80C until use. plotted as the ratio of ACE target count to total count
(ACE target count	ACE competitor count) versus the
RNA preparation known number of ACE competitor molecules. At the
competition equivalent point (gene target count to totalTotal RNA from kidney tissue was isolated using the
RNeasy Kit (Qiagen Inc., Chatsworth, CA, USA) accord- count  0.5), the original number of target mRNAs
corresponds to the initial number of competitor RNAing to the manufacturer’s directions. The samples were
first lysed and homogenized in guanidinium isothiocya- molecules used.
nate-containing buffer and then treated with a silica gel-
In situ hybridization for ACE mRNAbased membrane with the speed of microspin. The amount
of RNA was evaluated by absorption at 260 nm, using a A fragment of length 355 bp was obtained by PCR
with primers (1651 to 1674 and 1986 to 2005) with humanDU-60 spectrophotometer (Beckman Instruments Ltd.,
Fullerton, CA, USA). ACE cDNA [14] as the template. The fragment of 355 bp
(from position 1674 to 2005) was ligated in the pCRII
Construction of competitor RNA vector and linealized with Bgl II. C RNA probes were
obtained with the DIG RNA Labeling Kit (Boehringer,For construction of internal standard competitor RNAs,
shortened fragments of human cDNAs of ACE were Mannheim, Germany). The digoxigenin 5 end-labeled
antisense ACE C RNA probe was created by transcriptionmade and transcribed into RNA. The ACE competitor
template was obtained as previously reported [13] from using SP6 RNA polymerase after digestion with Xho I,
and the digoxigenin 5 end-labeled sense ACE C RNAa 951 bp ACE cDNA fragment with the sense primer:
5-CGCTACAACTTCGACTGGTGG-3 (1481 to 1501) probe was created by transcription using T7 RNA poly-
merase after digestion with BamH I. The in situ hybrid-and antisense primer: 5-CGGGTAAAACTGGAGGA
TGG-3 (2412 to 2431) by using human ACE cDNA [14] ization (ISH) procedure to identify ACE mRNA was
performed with Universal RISH & AP Detection Kitas a template in the PCR reaction. The PCR product was
ligated into a pCRII vector (TA CloningRKit; In- (Kreatech Diagnostics, Amsterdam, The Netherlands)
according to the manufacturer’s directions. ACE C RNAvitrogen, Carlsbad, CA, USA). Plasmid templates were
transcribed into RNA by using an SP6-RNA polymerase probe was applied on fresh frozen renal biopsy speci-
mens. The sections were examined by semiquantitativein vitro transcription kit (MEGAscript; Ambion Ltd.,
Austin, TX, USA). Competitor RNA templates were analysis. The tubules and glomeruli were scored as fol-
lows: 0  no signals; 1  trace signals; 2  definitestored at 80C until use.
signals; and 3  strong signals. At least 20 tubules and
Reverse transcription and competitive RNA-PCR 5 glomeruli were scored on each slide. A numerical aver-
age for each component was used to calculate the meanFor cDNA synthesis, equal amounts of total RNA
(100 ng) were mixed with various amounts of ACE com- score for each subject and for each group as a whole.
petitor RNA. Because interindividual renal ACE gene
Statistical analysisexpression was highly variable, PCR with [
-32P]dCTP
(hot PCR) was performed for the quantification of re- The calculation of allele frequency to test for Hardy-
Weinberg equilibrium for the subjects was carried out,nal ACE mRNA, followed by PCR without radioiso-
tope-labeled dCTP (cold PCR) for semiquantification. and the 2 test was used to compare expected against
observed frequencies of genotype. The difference of fre-Competitor RNA and target mRNA were reverse tran-
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Table 1. ACE genotype, clinical data, serum ACE and semiquantitative analysis of renal ACE mRNA signals by in situ hybridization
Semiquantitative renal ACE
mRNA signals by ISH
Gender Mean BP Serum creatinine Serum ACE
ACE genotype N Age M/F mm Hg mg/dL IU/L/37C Tubulesa Glomerulia
Healthy subjects 50 5111 15/35 918 0.610.14 12.44.9 1.80.6 1.40.7
II 20 5111 5/15 9110 0.600.11 9.63.4b 2.00.3 0.90.6
ID 23 5211 8/15 937 0.640.17 12.4 .36b 2.00.3 1.60.3
DD 7 4412 2/5 908 0.550.08 19.44.9 2.70.2 2.30.6
a The difference in three genotype groups was significant (P  0.01)
b P  0.01 compared with subjects with the DD genotype
Fig. 1. Angiotensin-converting enzyme (ACE) mRNA expression by
in situ hybridization (ISH) in kidney tissues from healthy subjects with
the ACE DD, ID, or II genotypes. ACE mRNA expression is strong
in DD (A), intermediate in ID (B) and weak in II (C ).
quencies of males in three genotype groups was also as- RESULTS
sessed by the 2 test. The correlations between renal Angiotensin-converting enzyme genotype, clinical data,
ACE transcripts and mean blood pressure were exam- serum ACE, and semiquantitative analysis of ACE
ined by linear regression analysis. Other data are pre- mRNA signals by ISH are given in Table 1. The frequen-
sented as means SD. Tukey’s method was used follow- cies of the I and D alleles were 63 and 37%, and the II,
ing one-way analysis of variance to evaluate the statistical ID, and DD genotypes observed were 20 (40%), 23
significance for the difference. The values that not nor- (46%), and 7 (14%), respectively, in our healthy sub-
mally distributed (data by ISH) were analyzed with jects. The expected values predicted by the assumption
Kruskal-Wallis rank method. Statistical significance was of Hardy-Weinberg equilibrium in the subjects were
similar to those observed in these subjects (II:ID:DD defined as P  0.05.
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Fig. 2. ACE mRNA semiquantification by
competitive RNA cold-polymerase chain reac-
tion (PCR). A constant amount of total RNA
extracted from a renal biopsy sample was
mixed with a decreasing number of ACE com-
petitor RNA molecules, reverse transcribed
into cDNA in the same tubes, and amplified
by PCR. ACE competitor RNA was prepared
in tenfold serial dilution. The PCR products
indicate ACE target (776 bp) and ACE com-
petitor (307 bp).
Fig. 3. ACE mRNA quantification by com-
petitive RNA hot-PCR. After recognition of
the competition equivalence point by cold
PCR, the same PCR series used shown in Fig-
ure 1 was performed except in a reaction mix-
ture containing [
-32P]dCTP. ACE competitor
RNA was prepared in twofold serial dilution.
The radioactivity of the ACE target and com-
petitor DNA was evaluated with an instant
imager.
39.7:46.6:13.7%, 2 test, P 0.05). There were no signifi- both tubular and glomerular ACE mRNA signals by
ISH were the highest in the DD, the lowest in the II,cant differences in age, mean blood pressure, and serum
creatinine levels between subjects with the II, ID, and and intermediate in the ID genotype in 50 healthy sub-
jects. The difference in three groups was significant (PDD genotypes. The male/female ratio was 5/15, 8/15,
and 2/5 in subjects with II, ID, and DD genotypes, respec- 0.01). Figure 1A depicts the ACE mRNA in a kidney
from a subject with the ACE DD genotype, and thetively. The frequency of males was low in all groups,
but the difference in three groups was not statistically mRNA is strongly expressed in both tubules and a glo-
merulus. Figure 1B shows ACE mRNA in kidney fromsignificant (II:ID:DD  25.0:34.8:28.6%, 2 0.495, P 
0.05). The serum ACE level was significantly higher in a subject with ACE ID genotype and mRNA was moder-
ately expressed. Figure 1C demonstrates the specimenthose with the DD genotype (19.4  4.9 IU/37C, N 
7) compared with those with either the ID (12.4  3.6 from a subject with the ACE II genotype with weak
mRNA expression in both the tubules and a glomerulus.IU/37C, N  23, P  0.01) or the II (9.6  3.4 IU/37C,
N  20, P  0.01) genotypes. The difference between Negative signals were documented in either tubules and
glomeruli after ISH with a sense ACE cRNA probe.subjects with the II and ID genotypes was not statistic-
ally significant. Semiquantitative analysis showed that Figure 2 shows representative renal ACE mRNA semi-
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sessing studies involving the ACE I/D genotype. Our sub-
jects were all Japanese, and a greater number of females
than males (35/15) in this study, reflecting a higher fre-
quency of kidney donation from mothers than fathers
in living-related renal transplantation in Japan. The male
ratio in II:ID:DD genotype groups was 25.0:34.8:28.6%,
but this difference was not statistically significant, and
we considered that the data obtained in this study were
valid to assess the effect of the ACE I/D genotype on
renal ACE mRNA in the Japanese population.
Competitive RNA-PCR used was internally standard-
ized, which prevents distortion of the results by varying
efficiency of the reverse transcription or PCR itself. The
variance of procedure and its reproducibility were sys-
temically investigated, and the variance was below 5%.
In addition, it is reported that ACE mRNA levels ob-
tained by this method correlated favorably with tradi-
tional slot blot hybridization [13]. These support its suit-
ability for ACE mRNA quantitation in our small renal
biopsy samples by this method.
It is accepted that the serum ACE level is associated
Fig. 4. Renal ACE transcripts and ACE I/D genotype in healthy sub- with the ACE I/D genotype. However, the mechanism
jects (N  50). has not been precisely defined. Consistent with the previ-
ous report on myocardial ACE gene expression [13],
interindividual renal ACE gene expression was highly
variable in our study. Our study in the healthy subjectsquantification by competitive RNA-cold PCR. Figure 3
showed that the number of ACE transcripts of totalshows representative ACE mRNA quantification by
mRNA in kidneys was significantly lower in subjects withcompetitive RNA-hot PCR. The band radioactivity of
the II genotype than in those with either the ID or DDthe ACE target and competitor DNA was evaluated.
genotype. These results were consistent with a report onThe correlation between the ACE gene target count to
left ventricle ACE mRNA that the expression variedtotal count versus the known number of ACE competitor
with ACE genotype and left ventricular function in isch-molecules was significant (N  5, r  0.99, P  0.01).
emic heart disease patients [19]. It also is reported thatAs shown in Figure 4, the number of ACE transcripts
ACE activity in human ventricular tissues is elevated inin 100 ng of total RNA was significantly (P 0.01) lower
subjects with the DD genotype compared with levels inin subjects with the II genotype (5.6  5.3  105, N 
subjects with the II or ID genotypes [3]. In contrast,20) compared with those with the ID (17.9  13.6  105,
atrial ACE mRNA expression was not associated withN  23) or the DD genotypes (36.9  14.6  105, N 
the ACE I/D genotype [20, 21]. The discrepancy between7). The difference between subjects with ID and DD
atria and ventricle may be derived from the differentgenotypes was also significant (P  0.01).
cell composition, and the discrepancy in atria and kidneyThe correlation between renal ACE transcripts and
may be derived from the difference of two tissues, sincemean blood pressure was not observed (r  0.007,
the regulation of genes may be tissue or cell specific. TheN  50).
significance of the ACE I/D genotype among different
organs of tissue depends on the local availability on an-
DISCUSSION giotensin I for conversion to angiotensin II by ACE. It
has been shown the angiotensin II/I ratio is markedlyThe frequencies of the II, ID and DD genotypes ob-
served in our 50 healthy subjects were 40, 46, and 14%, high in kidneys; this ratio averaged 0.3 and 2.0 in the
plasma and kidney of rats [22], although species-specificrespectively, and were distributed according to the Hardy-
Weinberg equilibrium. Ethnic variation in ACE I/D ge- regulation also is likely an issue, and it still remains
uncertain in humans. However, there is a possibility thatnotype is well known [15], and these data are similar to
in those Japanese healthy subjects reported by Yoshida the ACE I/D genotype may be particularly important at
the renal tissue level. Further study is needed to establishet al [12] (II:ID:DD 41:52:7%, 2 2.71, P 0.05) and
others [16, 17]. Gender-dependent association in ACE I/D that down-regulation of renal ACE mRNA in the II
genotype may be attributed to lower renal ACE levels,genotype in hypertension [15, 18] is reported. The effect of
ethnic variation and gender has a significant role in as- since the apparent discrepancy in human renal proximal
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